REAL-WORLD COMPARATIVE EFFECTIVENESS OF FIDAXOMICIN VS. VANCOMYCIN AMONG MEDICARE BENEFICIARIES WITH CLOSTRIDIOIDES DIFFICILE INFECTION

被引：0
|
作者：
Dubberke, Erik R.
Puckett, Justin T.
Obi, Engels N.
Kamal-Bahl, Sachin
Desai, Kaushal
Stuart, Bruce
Doshi, Jalpa A.
机构：
来源：
GASTROENTEROLOGY | 2022年 / 162卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
647
引用
收藏
页码：S157 / S157
页数：1
相关论文
共 50 条
  • [1] REAL-WORLD OUTCOMES ASSOCIATED WITH BEZLOTOXUMAB USE AMONG MEDICARE BENEFICIARIES WITH CLOSTRIDIOIDES DIFFICILE INFECTION
    Dubberke, E.
    Puckett, J.
    Obi, E. N.
    Kamal-Bahl, S.
    Desai, K.
    Stuart, B.
    Doshi, J.
    [J]. VALUE IN HEALTH, 2022, 25 (07) : S330 - S330
  • [2] The Clinical Effectiveness of Fidaxomicin Compared to Vancomycin in the Treatment of Clostridioides difficile Infection, A Single-Center Real-World Experience
    Alsoubani, Majd
    Chow, Jennifer K.
    Rodday, Angie Mae
    McDermott, Laura A.
    Walk, Seth T.
    Kent, David M.
    Snydman, David R.
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2024,
  • [3] Real-world effectiveness of fidaxomicin in patients at high risk of Clostridioides difficile recurrence
    Colwell, Benjamin
    Aguilar, Jennifer
    Hughes, Frances
    Goriacko, Pavel
    Chen, Victor
    Chang, Mei
    Bartash, Rachel
    Guo, Yi
    [J]. ANTIMICROBIAL STEWARDSHIP & HEALTHCARE EPIDEMIOLOGY, 2024, 4 (01):
  • [4] Real-World Budget Impact of Fidaxomicin versus Vancomycin or Metronidazole for In-Hospital Treatment of Clostridioides difficile Infection
    Whitney, Laura
    Nesnas, John
    Planche, Timothy
    [J]. ANTIBIOTICS-BASEL, 2023, 12 (01):
  • [5] A REAL-WORLD COMPARISON OF MORTALITY, HEALTHCARE RESOURCE UTILIZATION, AND COST AMONG MEDICARE BENEFICIARIES WITH CLOSTRIDIOIDES DIFFICILE INFECTION WITH AND WITHOUT SEPSIS
    Amin, Alpesh
    Nelson, Winnie W.
    Dahdal, David N.
    Dreyfus, Jill
    Wong, Anny C.
    Mohammadi, Iman
    Teigland, Christie
    [J]. GASTROENTEROLOGY, 2021, 160 (06) : S362 - S363
  • [6] Comparative Effectiveness of Fidaxomicin vs Vancomycin in Populations With Immunocompromising Conditions for the Treatment of Clostridioides difficile Infection: A Single-Center Study
    Alsoubani, Majd
    Chow, Jennifer K.
    Rodday, Angie Mae
    Kent, David
    Snydman, David R.
    [J]. OPEN FORUM INFECTIOUS DISEASES, 2024, 11 (01):
  • [7] Real-world effectiveness of approved anticancer agents among Medicare beneficiaries.
    Green, Angela
    Curry, Michael A.
    Bach, Peter
    Mailankody, Sham
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [8] A Real-World Comparison of Mortality, Healthcare Resource Utilization, and Cost Among Medicare Beneficiaries With Clostridioides difficile Infection (CDI) With and Without Inflammatory Bowel Disease (IBD)
    Feuerstadt, Paul
    Dahdal, David N.
    Wong, Anny C.
    Dreyfus, Jill
    Mohammadi, Iman
    Teigland, Christie
    Patel, Heena
    Amin, Alpesh
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S413 - S415
  • [9] A Real-World Comparison of Mortality, Health Care Resource Utilization, and Cost Among Medicare Beneficiaries With Clostridioides difficile Infection (CDI) With and Without Inflammatory Bowel Disease (IBD)
    Feuerstadt, P.
    Dahdal, D. N.
    Wong, A. C.
    Dreyfus, J.
    Mohammadi, I.
    Teigland, C.
    Patel, H.
    Amin, A.
    [J]. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2020, 70 : S49 - S50
  • [10] A Real-World Comparison of Mortality, Health Care Resource Utilization, and Cost Among Medicare Beneficiaries With Clostridioides difficile Infection (CDI) With and Without Inflammatory Bowel Disease (IBD)
    不详
    [J]. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2022, 70 : S49 - S50
12345